SEOUL, SOUTH KOREA – May 30, 2011 – The growth of high-quality clinical research in South Korea, one of Asia’s fastest-growing countries for biopharmaceutical development, is being boosted through a new partnership between the Korea National Enterprise for Clinical Trials (KoNECT) and Quintiles, the world’s largest biopharmaceutical services company.

KoNECT and Quintiles have signed a memorandum of understanding to collaborate in producing educational events involving investigators, local and multi-national biopharmaceutical companies and relevant government officials.

“This MOU is a further indication of Quintiles’ long-standing commitment to South Korea, where we first opened an office 11 years ago,” said MiSook Hyun, head of Quintiles’ Clinical Operations in South Korea. “With KoNECT we can further enhance the already high clinical research standards that exist here and expand its clinical research capacity.”

KoNECT and Quintiles anticipate working together on educational events beginning this summer.

“We are very proud to be working with Quintiles, a recognized leader in advancing clinical research and raising professionalism not only in Korea but globally,” said KoNECT President Sang-Goo Shin, M.D., Ph.D. “Together we hope to improve clinical research expertise and build a support infrastructure in Korea that’s second to none.”

Anand Tharmaratnam, M.D., Quintiles Senior Vice President and Head, Asia Markets, said: “This collaboration is part of Quintiles’ efforts across Asia-Pacific to advance high-quality clinical research in support of patients who are involved in trials to develop new medicines.”

About KoNECT

Established in 2007 with the support of the South Korean government, academic institutions and life-science industries, KoNECT provides clinical research resources, training and support. KoNECT’s vision is to establish an advanced clinical trial infrastructure and develop the nation’s biopharmaceutical industry to serve as an international hub for clinical trials.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit